European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). New psychoactive substances: 25 years of early warning and response in Europe: an update from the EU Early Warning System. LU: Publications Office; 2022.

Google Scholar 

Prekupec MP, Mansky PA, Baumann MH. Misuse of novel synthetic opioids: a deadly new trend. J Addict Med. 2017;11:256–65. https://doi.org/10.1097/ADM.0000000000000324.

Article  PubMed  PubMed Central  Google Scholar 

European Monitoring Centre for Drugs and Drug Addiction (EMCDDA). European drug report 2022: trends and developments. LU: Publications Office; 2022.

Google Scholar 

UNODC (2020) The growing complexity of the opioid crisis. Global SMART Update, Volume 24. Vienna

Krotulski AJ, Walton SE, Mohr ALA, Logan BK (2022) Trend Report Q3 2022: NPS opioids in the United States. https://www.cfsre.org/images/trendreports/2022-Q3-NPS-Opioids-Trend-Report.pdf. Accessed 26 Dec 2022

Vandeputte MM, Vasudevan L, Stove CP. In vitro functional assays as a tool to study new synthetic opioids at the μ-opioid receptor: Potential, pitfalls and progress. Pharmacol Therapeut. 2022;235:108161. https://doi.org/10.1016/j.pharmthera.2022.108161.

Article  CAS  Google Scholar 

Sharma KK, Hales TG, Rao VJ, NicDaeid N, McKenzie C. The search for the “next” euphoric non-fentanil novel synthetic opioids on the illicit drugs market: current status and horizon scanning. Forensic Toxicol. 2019;37:1–16. https://doi.org/10.1007/s11419-018-0454-5.

Article  CAS  PubMed  Google Scholar 

Kyei-Baffour K, Lindsley CW. DARK Classics in Chemical Neuroscience: U-47700. ACS Chem. Neurosci. 2020;11:3928–36. https://doi.org/10.1021/acschemneuro.0c00330.

Baumann MH, Tocco G, Papsun DM, Mohr AL, Fogarty MF, Krotulski AJ. U-47700 and its analogs: non-fentanyl synthetic opioids impacting the recreational drug market. Brain Sci. 2020;10:895. https://doi.org/10.3390/brainsci10110895.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ujváry I, Christie R, Evans-Brown M, Gallegos A, Jorge R, de Morais J, Sedefov R. DARK Classics in chemical neuroscience: etonitazene and related benzimidazoles. ACS Chem Neurosci. 2021;12:1072–92. https://doi.org/10.1021/acschemneuro.1c00037.

Article  CAS  PubMed  Google Scholar 

Vandeputte MM, Van Uytfanghe K, Layle NK, Germaine DM, Iula DM, Stove CP. Synthesis, chemical characterization, and μ-opioid receptor activity assessment of the emerging group of “nitazene” 2-benzylbenzimidazole synthetic opioids. ACS Chem Neurosci. 2021;12:1241–51. https://doi.org/10.1021/acschemneuro.1c00064.

Article  CAS  PubMed  Google Scholar 

Verougstraete N, Vandeputte MM, Lyphout C, Cannaert A, Hulpia F, Van Calenbergh S, Verstraete AG, Stove CP. First report on brorphine: the next opioid on the deadly new psychoactive substances’ horizon? J Anal Toxicol. 2020;44:937–46. https://doi.org/10.1093/jat/bkaa094.

Article  CAS  Google Scholar 

Vandeputte MM, Krotulski AJ, Papsun DM, Logan BK, Stove CP. The rise and fall of isotonitazene and brorphine: two recent stars in the synthetic opioid firmament. J Anal Toxicol. 2022;2:115–21. https://doi.org/10.1093/jat/bkab082.

Article  CAS  Google Scholar 

Kennedy NM, Schmid CL, Ross NC, Lovell KM, Yue Z, Chen YT, Cameron MD, Bohn LM, Bannister TD. Optimization of a series of mu opioid receptor (MOR) agonists with high G protein signaling bias. J Med Chem. 2018;61:8895–907. https://doi.org/10.1021/acs.jmedchem.8b01136.

Article  CAS  PubMed  PubMed Central  Google Scholar 

World Health Organization (2021) World Health Organization Model List of Essential Medicines - 22nd List, 2021. WHO/MHP/HPS/EML/2021.02. License CC BY-NC-SA 3.0 IGO, Geneva

Mattick RP, Breen C, Kimber J, Davoli M. Methadone maintenance therapy versus no opioid replacement therapy for opioid dependence. Cochrane Database Syst Rev. 2009; https://doi.org/10.1002/14651858.CD002209.pub2.

Strain E, Saxon AJ, Friedman M Medication for opioid use disorder. In: UpToDate. UpToDate Inc., Waltham, MA

Heidbreder C, Fudala PJ, Greenwald MK. History of the discovery, development, and FDA-approval of buprenorphine medications for the treatment of opioid use disorder. Drug Alcohol Depend Rep. 2023;6:100133. https://doi.org/10.1016/j.dadr.2023.100133.

Article  PubMed  PubMed Central  Google Scholar 

Huang P, Kehner GB, Cowan A, Liu-Chen L-Y. Comparison of pharmacological activities of buprenorphine and norbuprenorphine: norbuprenorphine is a potent opioid agonist. J Pharmacol Exp Therapeut. 2001;297:688–95.

CAS  Google Scholar 

Fatseas M, Auriacombe M. Why buprenorphine is so successful in treating opiate addiction in France. Current Psychiat Rep. 2007;9:358–64. https://doi.org/10.1007/s11920-007-0046-2.

Article  CAS  Google Scholar 

Dematteis M, Auriacombe M, D’Agnone O, Somaini L, Szerman N, Littlewood R, Alam F, Alho H, Benyamina A, Bobes J, Daulouede JP, Leonardi C, Maremmani I, Torrens M, Walcher S, Soyka M. Recommendations for buprenorphine and methadone therapy in opioid use disorder: a European consensus. Expert Opin Pharmacother. 2017;18:1987–99. https://doi.org/10.1080/14656566.2017.1409722.

Article  CAS  PubMed  Google Scholar 

Raffa RB, Haidery M, Huang H-M, Kalladeen K, Lockstein DE, Ono H, Shope MJ, Sowunmi OA, Tran JK, Pergolizzi JV. The clinical analgesic efficacy of buprenorphine. J Clin Pharm Ther. 2014;39:577–83. https://doi.org/10.1111/jcpt.12196.

Article  CAS  PubMed  Google Scholar 

Gillis A, Gondin AB, Kliewer A, Sanchez J, Lim HD, Alamein C, Manandhar P, Santiago M, Fritzwanker S, Schmidel F, Katte TA, Reekie T, Grimsey NL, Kassiou M, Kellam B, Krasel C, Halls ML, Connor M, Lane JR, et al. Low intrinsic efficacy for G protein activation can explain the improved side effect profiles of new opioid agonists. Sci Signal. 2020;13:eaaz3140. https://doi.org/10.1126/scisignal.aaz3140.

Article  CAS  PubMed  Google Scholar 

Coe MA, Lofwall MR, Walsh SL. Buprenorphine Pharmacology Review: Update on Transmucosal and Long-acting Formulations. J Addict Med. 2019;13:93–103. https://doi.org/10.1097/ADM.0000000000000457.

Article  PubMed  PubMed Central  Google Scholar 

Brown SM, Campbell SD, Crafford A, Regina KJ, Holtzman MJ, Kharasch ED. P-glycoprotein is a major determinant of norbuprenorphine brain exposure and antinociception. J Pharmacol Exp Ther. 2012;343:53–61. https://doi.org/10.1124/jpet.112.193433.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Scott CC, Robbins EB, Chen KK. Comparison of Some New Analgesic Compounds. Science. 1946;104:587–8. https://doi.org/10.1126/science.104.2712.587.

Article  CAS  PubMed  Google Scholar 

Scott CC, Kohlstaedt KG, Chen KK. Comparison of the pharmacologic properties of some new analgesic substances. Anesth Analg. 1947;26:12–7.

Article  CAS  Google Scholar 

Bockmühl M, Ehrhart G. Über eine neue Klasse von spasmolytisch und analgetisch wirkenden Verbindungen, I. Justus Liebigs Ann Chem. 1949;561:52–86. https://doi.org/10.1002/jlac.19495610107.

Article  Google Scholar 

Lenz GR. Opiates. Orlando: Academic Press; 1986.

Google Scholar 

Janssen PAJ, Jageneau AH. A new series of potent analgesics. J. Pharm. Pharmacol. 1957;9:381–400. https://doi.org/10.1111/j.2042-7158.1957.tb12290.x.

Article  CAS  PubMed  Google Scholar 

UNODC (1975) The international drug control conventions: schedules of the single convention on narcotic drugs of 1961, as amended by the 1972 Protocol

National Forensic Laboratory Slovenia (2021) Analytical report: Dipyanone (C23H29NO). https://www.policija.si/apps/nfl_response_web/0_Analytical_Reports_final/Dipyanone-ID-2955-21_report.pdf. Accessed 11 Jan 2023

Krotulski AJ, McBride A, Brown K, Fogarty MF, Logan BK Dipyanone. In: NPS Discovery. https://www.cfsre.org/images/monographs/Dipyanone_031422_NMSLabs_Report.pdf. Accessed 15 Mar 2022

Richards GC, Sitkowski K, Heneghan C, Aronson JK. The oxford catalogue of opioids: a systematic synthesis of opioid drug names and their pharmacology. Brit Jnl Clinical Pharma. 2021;87:3790–812. https://doi.org/10.1111/bcp.14786.

Van Proosdij-Hartzema EG, De Jongh DK. A series of potent analgesics (Abstract only). Acta Physiol Pharmacol Neerl. 1957;5:398–405.

PubMed  Google Scholar 

NV Nederlandsche Combinatie voor Chemische Industrie, Laboratoria Pharmaceutica Dr. C. Janssen NV (1959) Analgesically active substituted α,α-diphenyl-γ-aminobutyramides. GB Patent 822,055.

Andersen S, Dickenson AH, Kohn M, Reeve A, Rahman W, Ebert B. The opioid ketobemidone has a NMDA blocking effect. Pain. 1996;67:369–74. https://doi.org/10.1016/0304-3959(96)03123-5.

Article  CAS  PubMed  Google Scholar 

CIBA. Manufacture of Piperidyl Ketones. GB Patent. 1948;609:763.

Google Scholar 

Vandeputte MM, Persson M, Walther D, Vikingsson S, Kronstrand R, Baumann MH, Gréen H, Stove CP. Characterization of recent non-fentanyl synthetic opioids via three different in vitro μ-opioid receptor activation assays. Arch. Toxicol. 2022;96:877–97. https://doi.org/10.1007/s00204-021-03207-9.

Article  CAS  PubMed  Google Scholar 

Lamy FR, Daniulaityte R, Barratt MJ, Lokala U, Sheth A, Carlson RG. “Etazene, safer than heroin and fentanyl”: Non-fentanyl novel synthetic opioid listings on one darknet market. Drug Alcohol Depend. 2021;225:108790. https://doi.org/10.1016/j.drugalcdep.2021.108790.

Article  CAS  PubMed  Google Scholar 

Miescher K, Kaegi H Esters of 1-alkyl-4-hydroxyphenylpiperidiyl-4-ketones. US Patent. 1949 2, 486,796.

Kesha K, Boggs CL, Ripple MG, Allan CH, Levine B, Jufer-Phipps R, Doyon S, Chi P, Fowler DR. Methylenedioxypyrovalerone (“Bath Salts”),Related Death: Case Report and Review of the Literature. J Forensic Sci. 2013;58:1654–9. https://doi.org/10.1111/1556-4029.12202.

Article  CAS  PubMed  Google Scholar 

Vasudevan L, Vandeputte MM, Deventer M, Wouters E, Cannaert A, Stove CP. Assessment of structure-activity relationships and biased agonism at the Mu opioid receptor of novel synthetic opioids using a novel, stable bio-assay platform. Biochem Pharmacol. 2020;177:113910. https://doi.org/10.1016/j.bcp.2020.113910.

Article  CAS  PubMed  Google Scholar 

Cannaert A, Deventer M, Fogarty M, Mohr ALA, Stove CP. Hide and Seek: Overcoming the Masking Effect of Opioid Antagonists in Activity-Based Screening Tests. Clin Chem. 2019;65:1604–5. https://doi.org/10.1373/clinchem.2019.309443.

Article  CAS  PubMed  Google Scholar 

Cannaert A, Vasudevan L, Friscia M, Mohr ALA, Wille SMR, Stove CP. Activity-based concept to screen biological matrices for opiates and (synthetic) opioids. Clin Chem. 2018;64:1221–9. https://doi.org/10.1373/clinchem.2018.289496.

Article  CAS  PubMed  Google Scholar 

Krotulski AJ, Mohr ALA, Kacinko SL, Fogarty MF, Shuda SA, Diamond FX, Kinney WA, Menendez MJ, Logan BK. 4F-MDMB-BINACA: A New Synthetic Cannabinoid Widely Implicated in Forensic Casework. J Forensic Sci. 2019;64:1451–61. https://doi.org/10.1111/1556-4029.14101.

Article  CAS  PubMed  Google Scholar 

Krotulski AJ, Papsun DM, Kacinko SL, Logan BK. Isotonitazene Quantitation and Metabolite Discovery in Authentic Forensic Casework. J Analyt Toxic. 2020;44:521–30. https://doi.org/10.1093/jat/bkaa016.